---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-013838"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:34:18.841593+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eton submits NDA to FDA for ET-400 hydrocortisone oral solution; approval expected Q1 2025

## Summary
- NDA submitted for ET-400, a proprietary patented hydrocortisone oral solution.
- Company expects 10-month FDA review; potential approval and launch in Q1 2025.
- Combined peak sales of ET-400 and Alkindi Sprinkle forecast to exceed $50M annually.
- ET-400 has patent protection through 2043; additional patent applications under review.

## SEC filing metadata
- accession: 0001437749-24-013838
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924013838/0001437749-24-013838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924013838/eton20240426c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-013838
- JSON: https://secwatch.observer/filing/0001437749-24-013838.json
- Plain text: https://secwatch.observer/filing/0001437749-24-013838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.